Posts by: Patricia Inacio, PhD

Patricia Inacio, PhD

Patricia holds her Ph.D. in Cell Biology from University Nova de Lisboa, and has served as an author on several research projects and fellowships, as well as major grant applications for European Agencies. She also served as a PhD student research assistant in the Laboratory of Doctor David A. Fidock, Department of Microbiology & Immunology, Columbia University, New York.

June 13, 2019June 20, 2019

Takhzyro Induces Rapid Resolution of Hereditary Angioedema Attacks, New Data Analysis Shows

News

Treatment with Takhzyro (lanadelumab) effectively reduces the number of attacks in patients with hereditary angioedema even in early phases of treatment, new analysis of data from the Phase 3 HELP ... Read more

August 2, 2018

BioCryst’s BCX7353 Prevents Attacks in HAE Patients, Phase 2 Trial Shows

News

Daily treatment with BCX7353, an investigative oral inhibitor of plasma kallikrein, reduces the rate of attacks in hereditary angioedema (HAE) patients by more than 70%, a Phase 2 study shows. Also, more patients ... Read more

June 19, 2018

Delayed Angioedema Diagnosis Has Significant Impact on Family Caregivers, Study Says

News

Delays in the diagnosis of hereditary angioedema causes family caregivers to feel fear, anxiety, and uncertainty, according to a study focused on better understanding what these caregivers go through during the ... Read more

June 5, 2018

KalVista Confirms Mechanism of Action of Potential HAE Therapy KVD900

News

KVD900, a potential new approach for treating hereditary angioedema, prevents the breakdown of kininogen and subsequent buildup of bradykinin — the underlying cause of the disease, KalVista Pharmaceuticals announced. The company confirmed this ... Read more

May 10, 2018

Two Genes May Be Therapeutic Targets for Acute Hereditary Angioedema, Study Finds

News

Comparing the genetic profile of patients with hereditary angioedema during remission and in acute attacks, researchers identified two genes that seem to participate in edema formation. The genes – ... Read more

March 22, 2018

Investigational BCX7353 Delivered to First Patient in APeX-2 Trial

News

A Phase 3 trial testing BCX7353, an inhibitor of plasma kallikrein for the prevention of swelling attacks in hereditary angioedema (HAE) patients, has dosed its first participant, BioCryst Pharmaceuticals announced. The ... Read more

March 21, 2018March 21, 2018

Lanadelumab Reduces Hereditary Angioedema Attacks, HELP Study Data Show

News

Lanadelumab, an antibody that binds and inhibits plasma kallikrein, effectively reduces the number of swelling attacks and improves quality-of-life scores in patients with hereditary angioedema (HAE) when used as a ... Read more

March 8, 2018March 8, 2018

BioCryst Starts Long-Term Trial of BCX7353’s Ability to Prevent Hereditary Angioedema Attacks

News

A long-term clinical trial testing BCX7353’s ability to prevent hereditary angioedema (HAE) attacks is dosing its first group of participants, BioCryst Pharmaceuticals announced. “Initiation of the APeX-S trial is an ... Read more

February 15, 2018February 15, 2018

Pregnant Women with Hereditary Angioedema May Benefit from Long-term Treatment with Berinert, Report Suggests

News

Long-term treatment with human plasma-derived C1 inhibitor may help women with hereditary angioedema get pregnant and carry out the pregnancy to full term without risking complications, a case report suggests. The ... Read more

February 1, 2018February 1, 2018

Shire to Seek FDA Marketing Approval for Lanadelumab as Therapy for Hereditary Angioedema

News

The biopharmaceutical company Shire is expected to soon submit a biologics license application to the U.S. Food and Drug Administration (FDA) seeking marketing approval of its investigational monoclonal antibody lanadelumab as ... Read more

Pin It on Pinterest